Free Trial
NASDAQ:QLGN

Qualigen Therapeutics (QLGN) Stock Price, News & Analysis

Qualigen Therapeutics logo
$3.56 +0.05 (+1.28%)
As of 07/11/2025 04:00 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Qualigen Therapeutics Stock (NASDAQ:QLGN)

Key Stats

Today's Range
$3.37
$3.89
50-Day Range
$3.26
$3.98
52-Week Range
$2.85
$29.44
Volume
45,396 shs
Average Volume
87,787 shs
Market Capitalization
$5.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive QLGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Qualigen Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

QLGN Stock News Headlines

Qualigen Therapeutics, Inc. (QLGN) - Yahoo Finance
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
See More Headlines

QLGN Stock Analysis - Frequently Asked Questions

Qualigen Therapeutics' stock was trading at $4.21 at the start of the year. Since then, QLGN shares have decreased by 18.8% and is now trading at $3.42.

Qualigen Therapeutics, Inc. (NASDAQ:QLGN) released its quarterly earnings results on Tuesday, August, 15th. The company reported ($34.50) EPS for the quarter, missing analysts' consensus estimates of ($26.00) by $8.50. The firm had revenue of $1.63 million for the quarter, compared to the consensus estimate of $1.60 million.

Shares of Qualigen Therapeutics reverse split on Tuesday, November 5th 2024.The 1-50 reverse split was announced on Friday, November 1st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Monday, November 4th 2024. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

Shares of QLGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Qualigen Therapeutics investors own include Predictive Oncology (POAI), Ford Motor (F), Zomedica (ZOM), Bank of America (BAC), Wells Fargo & Company (WFC), JPMorgan Chase & Co. (JPM) and Abbott Laboratories (ABT).

Company Calendar

Last Earnings
8/15/2023
Today
7/12/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - DRUGS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:QLGN
CIK
1460702
Fax
N/A
Employees
50
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.33
Quick Ratio
2.33

Sales & Book Value

Annual Sales
$4.98 million
Price / Sales
1.13
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.12) per share
Price / Book
-0.83

Miscellaneous

Outstanding Shares
1,640,000
Free Float
1,606,000
Market Cap
$5.61 million
Optionable
Not Optionable
Beta
0.03
10 Stocks Set to Soar in Summer 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:QLGN) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners